The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report

A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis

(2019) Al-Rahim R. Habib et al.   Scientific Reports

Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor

(2018) Andres Carrion et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Ivacaftor treatment of cystic fibrosis in children aged 12 to

(2018) Margaret Rosenfeld et al.   Lancet Respiratory Medicine

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

(2017) Steven M. Rowe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of CFTR Modulation on Intestinal pH, Motility and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation

(2017) Daniel Gelfond et al.   Clinical and Translational Gastroenterology

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

(2016) Jane C Davies et al.   Lancet Respiratory Medicine

Pilot evaluation of ivacaftor for chronic bronchitis

(2016) George M Solomon et al.   Lancet Respiratory Medicine

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis

(2013) James A. Lambert et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Type of CFTR Mutation Determines Risk of Pancreatitis in Patients With Cystic Fibrosis

(2010) Chee Y. Ooi et al.   GASTROENTEROLOGY

The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype

(2009) Arie Augarten et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY